Market Research Logo

Hemagglutinin 5 (H5) - Pipeline Review, H2 2016

Hemagglutinin 5 (H5) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Hemagglutinin 5 (H5) - Pipeline Review, H2 2016’, provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics.

The report provides comprehensive information on the Hemagglutinin 5 (H5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.
Scope
  • The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5)
  • The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Hemagglutinin 5 (H5) Overview
Therapeutics Development
Hemagglutinin 5 (H5) - Products under Development by Stage of Development
Hemagglutinin 5 (H5) - Products under Development by Therapy Area
Hemagglutinin 5 (H5) - Products under Development by Indication
Hemagglutinin 5 (H5) - Pipeline Products Glance
Early Stage Products
Hemagglutinin 5 (H5) - Products under Development by Companies
Hemagglutinin 5 (H5) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development
Altravax Inc
Ilyang Pharmaceutical Co Ltd
Inovio Pharmaceuticals Inc
NewLink Genetics Corp
Vaxine Pty Ltd
Hemagglutinin 5 (H5) - Drug Profiles
DPC-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IY-7640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3400X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemagglutinin 5 (H5) - Dormant Projects
Hemagglutinin 5 (H5) - Featured News & Press Releases
Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine
Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial
May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine
Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies
Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial
Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine
Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial
Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines
Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award
Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial
Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine
Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies
Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Altravax Inc, H2 2016
Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2016
Pipeline by Inovio Pharmaceuticals Inc, H2 2016
Pipeline by NewLink Genetics Corp, H2 2016
Pipeline by Vaxine Pty Ltd, H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report